Leveraging the holistic benefits of biosimilars in Europe – part 2: how payers can safeguard the future of a healthy biosimilar market environment

Figures & data

Figure 1. The three stages of the market maturity framework.^a

^aBiosimilar markets can be thought of in three stages of ‘maturity,’ which is broadly correlated to the level of access to biologic medicines within the therapy area; therefore, it is possible for a country to be in different stages of maturity for different molecules or therapy areas. Stakeholders may have specific goals for several molecules existing in parallel. In each stage of ‘maturity’ there are unique opportunities for stakeholders to capture the broad range of benefits that biosimilars can deliver; the methods by which these benefits can be captured will depend on their market landscape and specific goals of the stakeholders. Ultimately, this framework is not designed to be used for a strict categorization of countries, but rather, it should be used as a guide to support key stakeholders in their policy decision making process in order to achieve their specific goals for maximizing the number of biosimilar-generated benefits they are able to capture.

Figure 2. Estimated value of biologic products faced with loss of exclusivity in Europe (2010‒2029). (Reproduced from, the impact of biosimilar competition in Europe, Troein, P., Newton, M., Scott, K. © IQVIA Inc. 2020; by permission of IQVIA Inc.) [8].

ATC = anatomical therapeutic chemical; LOE = loss of exclusivity.

*Major molecules = sales >3Bn€ at LOE-1; ^†High-value molecules = sales >1Bn€ at LOE-1.

Sources: IQVIA MIDAS Q4 2019 (accessed Nov 2020), IQVIA ARK Patent Intelligence, IQVIA ForecastLink for data post-2020.

Notes: The intellectual property for biologicals can involve multiple patents and patent timelines for each individual product and therefore it is difficult to give an exact date for patent expiry for biologicals. It should be noted that these results are estimates as determined from IQVIA MIDAS® and ARK Patent Intelligence where available. Biologic prescriptions in 23 European countries.

Troein P, Newton M, Scott K. The impact of biosimilar competition in Europe. 2020 [ updated 2020 Dec; cited 2023 Jun 27]. updated 2020 Dec: https://health.ec.europa.eu/system/files/2021-01/biosimilar_competition_en_0.pdf

 Google Scholar

Data availability statement

Not applicable.